...
机译:H 2 MAB-119的建立,一种抗人表皮生长因子受体2单克隆抗体,对抗胰腺癌
Department of Antibody Drug Development Tohoku University Graduate School of Medicine Sendai;
Department of Antibody Drug Development Tohoku University Graduate School of Medicine Sendai;
Department of Antibody Drug Development Tohoku University Graduate School of Medicine Sendai;
Department of Antibody Drug Development Tohoku University Graduate School of Medicine Sendai;
Department of Oral and Maxillofacial Surgery Graduate School of Medical and Dental Sciences Tokyo;
Department of Pathology and Laboratory Medicine Sendai Medical Center Sendai Japan.;
Department of Antibody Drug Development Tohoku University Graduate School of Medicine Sendai;
Department of Antibody Drug Development Tohoku University Graduate School of Medicine Sendai;
HER2; monoclonal antibody; immunohistochemistry; pancreatic cancer;
机译:H 2 MAB-119的建立,一种抗人表皮生长因子受体2单克隆抗体,对抗胰腺癌
机译:晚期非小细胞肺癌患者抗人表皮生长因子受体3(HER3)单克隆抗体Patritumab的预测生物标记物的临床翻译和验证
机译:尼莫妥珠单抗(一种人源化单克隆抗表皮生长因子受体(EGFR)抗体)在患有局部晚期或转移性胰腺癌的患者中的II期研究。
机译:西妥昔单抗缀合的近红外硫化银量子点靶向表皮生长因子受体(EGFR)阳性胰腺癌细胞系
机译:针对人表皮生长因子受体的生物仿制药嵌合单克隆抗体的克隆和表达及其在CHO细胞中的产生,用于治疗结肠直肠癌。
机译:H2mab-19抗人表皮生长因子受体2单克隆抗体在小鼠口腔癌异种移植物中施加抗肿瘤活性
机译:patritumab(一种抗人表皮生长因子受体3(HER3)单克隆抗体,用于晚期非小细胞肺癌患者的预测生物标志物的临床转化和验证